SP
BravenNow
Adaptive Biotechnologies’ president Rubinstein sells $802k in ADPT stock
| USA | economy | ✓ Verified - investing.com

Adaptive Biotechnologies’ president Rubinstein sells $802k in ADPT stock

#Adaptive Biotechnologies #ADPT #stock sale #insider trading #Rubinstein #biotech #SEC filing

📌 Key Takeaways

  • Adaptive Biotechnologies' President Rubinstein sold $802,000 worth of ADPT stock
  • The sale involved company stock, indicating insider trading activity
  • The transaction is publicly disclosed as per regulatory requirements
  • Such sales can influence investor sentiment and stock market perception

🏷️ Themes

Insider Trading, Biotechnology

📚 Related People & Topics

ADPT

Topics referred to by the same term

ADPT may refer to one of the following: Arkansas Department of Parks, Heritage, and Tourism, formerly Arkansas Department of Parks, and Tourism.

View Profile → Wikipedia ↗
SEC filing

SEC filing

Type of financial statements in the United States

# SEC Filing An **SEC filing** is a formal financial statement or regulatory document submitted to the **U.S. Securities and Exchange Commission (SEC)**. These filings are mandatory requirements designed to ensure transparency, providing a standardized method for disclosing material information to ...

View Profile → Wikipedia ↗

Rubinstein

Surname list

Rubinstein is a surname of Ashkenazi Jews. It comes from German and Yiddish, where it means "ruby-stone".

View Profile → Wikipedia ↗

Entity Intersection Graph

Connections for ADPT:

🌐 Rubinstein 1 shared
View full profile

Mentioned Entities

ADPT

Topics referred to by the same term

SEC filing

SEC filing

Type of financial statements in the United States

Rubinstein

Surname list

Deep Analysis

Why It Matters

This news matters because insider stock sales by high-level executives can signal their confidence in the company's future prospects, potentially influencing investor sentiment and stock prices. It affects current shareholders who may interpret this as a bearish signal, potential investors evaluating the company's leadership confidence, and market analysts tracking insider trading patterns. The timing and size of such sales are particularly scrutinized in volatile biotech sectors where company valuations often hinge on clinical trial results and regulatory approvals.

Context & Background

  • Adaptive Biotechnologies (ADPT) is a commercial-stage biotechnology company focused on immune medicine, developing products based on immune-driven data from its proprietary immune medicine platform.
  • Insider trading regulations require executives to report stock transactions within specific timeframes, making such sales publicly visible and subject to market interpretation.
  • Biotechnology stocks like ADPT are often highly volatile due to their dependence on clinical trial outcomes, FDA approvals, and partnership announcements, making insider trading activity particularly noteworthy to investors.

What Happens Next

Investors will monitor whether other executives follow with similar sales, which could indicate broader leadership concerns. The company's next quarterly earnings report will be scrutinized for performance indicators that might explain the sale timing. Market analysts may adjust their price targets based on this insider activity combined with upcoming clinical trial data releases expected in the next 6-12 months.

Frequently Asked Questions

Why would a company president sell stock?

Executives may sell stock for personal financial planning reasons unrelated to company performance, such as diversification, tax planning, or major purchases. However, large sales can sometimes indicate concerns about future valuation or upcoming challenges.

How does this affect ADPT stock price?

Significant insider sales can create downward pressure on stock prices as investors interpret them as lack of confidence. The impact depends on the sale size relative to total holdings and whether other insiders are buying or selling simultaneously.

Is this type of stock sale illegal?

No, legal insider trading involves properly reported transactions by company executives following SEC regulations. Illegal insider trading involves trading based on material non-public information, which this reported sale does not indicate.

What percentage of Rubinstein's holdings does this represent?

Without specific holding details, we cannot determine the percentage, but SEC filings would show whether this represents a small portion for diversification or a significant reduction in position.

Should investors follow insider trading activity?

Many investors track insider transactions as one data point among many, recognizing that executives have legitimate personal reasons to sell that may not reflect company prospects. Consistent patterns across multiple insiders are more significant than isolated transactions.

}
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Iran conflict latest: Trump pauses Iran energy plant strikes by 10 days Solid rebound in Hormuz tanker flows backs Trump’s claim Oil pares some gains as Trump extends pause on Iran energy infrastructure attacks Gold falls on mixed messaging regarding Iran; Trump asserts peace talks ongoing (South Africa Philippines Nigeria) Adaptive Biotechnologies’ president Rubinstein sells $802k in ADPT stock By Insider Trading Published 03/26/2026, 07:46 PM Adaptive Biotechnologies’ president Rubinstein sells $802k in ADPT stock 0 ADPT -1.34% Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp (NASDAQ:ADPT) , sold a total of 57,180 shares of common stock between March 24 and March 26, 2026. The sales, executed under a pre-arranged 10b5-1 trading plan, fetched prices ranging from $13.70 to $14.27, totaling approximately $802,235. The stock currently trades at $13.96, reflecting a remarkable 69% gain over the past year, though InvestingPro analysis suggests the company appears on the most overvalued list based on its Fair Value assessment. The Adaptive Biotechnologies ’ President also acquired 44,166 shares of common stock through option exercises at a price of $7.27, amounting to $321,086. Following these transactions, Rubinstein directly owns 468,892 shares of Adaptive Biotechnologies Corp. For investors seeking deeper insights into ADPT’s valuation and growth prospects, the company is among 1,400+ US equities covered by comprehensive Pro Research Reports, available exclusively on InvestingPro . In other recent news, Adaptive Biotechnologies Corp reported its fourth-quarter 2025 earnings, surpassing analyst expectations with notable results. The company posted an earnings per share of -$0.09, significantly better than the forecasted -$0.18, representing a 50% positive surprise. Revenue for the quarter reached $71.7 million, exceeding the projected $59.33 million by 20.85%. BTIG raised its price target for...
Read full article at source

Source

investing.com

More from USA

News from Other Countries

🇬🇧 United Kingdom

🇺🇦 Ukraine